NCT03642080

MRI Predictors of Response to Tumor Treating Fields

Imaging Biomarkers to Predict Responsiveness to Tumor Treating Fields in Patients With High Grade Glioma

• Status: Unknown
• Phase: —
• Study type: Observational
• Enrollment: 48 (estimated)
• Sponsor: New York Presbyterian Brooklyn Methodist Hospital · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: —

Summary

Patients with glioblastoma, an aggressive brain tumor, are recommended to undergo treatment with tumor treating fields using the Optune device as part of standard of care therapy. While undergoing treatment, patients are monitored regularly with brain MRI scans to look for tumor progression, but there are currently no means to predict which, or when, patients will progress. The purpose of the current study is to prospectively analyze these MRI scans to look for subtle imaging markers that can predict for future brain tumor progression while undergoing tumor treating field therapy.

Detailed description

The proposed trial involves the prospective collection of imaging data at standard clinical time points before and during treatment with TTFields. All patients who are offered treatment with TTFields will also be offered enrollment in this non-randomized, observational study. Imaging data will include the standard battery of MRI sequences, which includes DWI and ADC reconstruction. These data will be collected at standard time points and the proposed study will not rely on any additional imaging or tests outside of the clinical standard of care.

Conditions

• Glioblastoma Multiforme

Timeline

• Start date: 2018-12-01
• Primary completion: 2021-09-30
• Completion: 2023-12-31
• First posted: 2018-08-22
• Last updated: 2018-12-19

Locations

1 site across 1 country: United States